Description
Cell-permeable. A slow-release prodrug version of Ro 61-8048, an inhibitor of KMO (kynurenine 3-monooxygenase), the enzyme that controls the kynurenine pathway, long believed to be implicated in neurodegeneration. JM6 reverses and prevents symptoms of neurodegenerative diseases like Alzheimer’s and Huntington’s in animal models. JM6 does not penetrate into the brain, but works by inhibiting KMO in the blood